Rare Diseases: Natural History Studies for Drug Development: Draft Guidance for Industry
Detailed guidance document from FDA and regulatory agencies.
Document Details
Guidance Document
March 25, 2019
April 15, 2020
a0f2f4af-4b97-4e7b-8e82-b4911a5d32e4
Related Documents
Labeling for Biosimilar and Interchangeable Biosimilar Products
Guidance DocumentSeptember 18, 2023Center for Drug Evaluation and Research
Rare Diseases: Early Drug Development and the Role of Pre-IND Meetings : Draft Guidance for Industry
Guidance DocumentOctober 16, 2018Center for Drug Evaluation and Research
Early Alzheimer’s Disease: Developing Drugs for Treatment
Guidance DocumentMarch 12, 2024Center for Drug Evaluation and Research
Quick Actions
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.
Try KeyPedia Today
Explore our real use cases and discover our features in depth.
Subscribe to our newsletter
Get the latest updates and insights delivered to your inbox